Roidosanal®

Roidosanal®

For Relief from Piles (Hemorrhoids) and Anal Fissures

Hemorrhoids is a frequently encountered complaint in clinical practice. The number of patients suffering from hemorrhoids has been steadily rising and the need for better and safer treatment options has been a long standing and unmet need.
Hemorrhoids are often not associated with any symptoms and people may be unaware they have them. However, if symptoms do develop, they may include the following:
  • Bleeding and/or pain on passing a stool
  • A lump around or inside the anus
  • Sense that bowel emptying has been incomplete
  • Itchiness or soreness around the anus
  • Mucus discharge from the anus

Based on the market scenario, the global market for hemorrhoids treatment is expected to grow at a CAGR of 5.5% by 2025

Roidosanal® – is a proprietary formulation and is a combination of 4 specifically selected phyto-ingredients

Standardized to contain not less than 7% total Catechins & epicatechins

Roidosanal® – Mode of Action in Hemorrhoids and Anal Fissures:

Clinical evidence rules in favor of Roidosanal®, in head on comparison with Daflon*

Roidosanal® has extensive safety and efficacy data and has been tried in comparative studies, against Daflon* (a mainstay in Hemorrhoids management).  In a head-on study against Daflon*, Roidosanal® significantly outperformed Daflon* as explained:
  • Roidosanal® showed better efficacy and faster resolution of signs and symptoms in patients with Grade III hemorrhoids. A significantly higher number of patients with Grade III hemorrhoids improved with Roidosanal® v/s Daflon (P value < 0.05; total of 200 patients were split into the Roidosanal® and Daflon groups)
  • Daflon and Roidosanal® were comparable to each other with respect to haemorrhoids related pain control
  • Fewer patients had bleeding in the Roidosanal® group v/s Daflon
  • With Roidosanal®, 82.83% of patients assessed that the treatment made them ‘A lot better’ as compared to only 48.51% in Daflon® group
  • With Roidosanal® 20.2% of patients’ treatment outcome was assessed as, Excellent’ by the investigators as compared to only 0.99% of patients in Daflon® group
  • Significantly less (P < .01 and p < .001) number of patients on Roidosanal® experience bleeding, pain, itching, soiling, tenesmus, irritation after defecation and constipation as compared to Daflon® on Day 7 as well as Day 15 of therapy
Roidosanal® therapy is pain-free, quick, economical, effective and safe and a better option than Daflon – as a substitute to surgery in early cases
* Daflon is a registered brand owned by Serdia Pharmaceuticals pvt ltd in India, and Servier pharmaceuticals globally.